Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to madulation of the dopamine D3 receptor

Details for Australian Patent Application No. 2005293694 (hide)

Owner Abbott GmbH & Co. KG

Inventors Drescher, Karla; Braje, Wilfried; Henry, Christophe; Grandel, Roland; Turner, Sean C.; Haupt, Andreas; Unger, Liliane

Agent Spruson & Ferguson

Pub. Number AU-B-2005293694

PCT Pub. Number WO2006/040178

Priority 60/618,776 14.10.04 US; 60/711,942 26.08.05 US

Filing date 14 October 2005

Wipo publication date 20 April 2006

Acceptance publication date 1 December 2011

International Classifications

C07D 311/04 (2006.01) Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings

A61K 31/13 (2006.01) - Amines, e.g. amantadine

A61K 31/35 (2006.01) - having six-membered rings with one oxygen as the only ring hetero atom

A61K 31/47 (2006.01) - Quinolines

A61P 25/16 (2006.01) Drugs for disorders of the nervous system

C07C 211/19 (2006.01) Compounds containing amino groups bound to a carbon skeleton

C07D 215/38 (2006.01) Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems

Event Publications

31 May 2007 PCT application entered the National Phase

  PCT publication WO2006/040178 Priority application(s): WO2006/040178

1 December 2011 Application Accepted

  Published as AU-B-2005293694

29 March 2012 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005293697-4-phenylsulfonamidopiperidines as calcium channel blockers

2005293693-6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor